Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
35,673
27,213
17,423
9,566
7,588
2,120
Hasılat Artışı (YoY)
51%
56%
82%
26%
258%
-28%
Satınalma Maliyeti
4,997
4,263
2,710
1,903
1,061
485
Brüt Kâr
30,675
22,950
14,713
7,663
6,527
1,634
Satış, Genel ve İdari
14,684
13,254
10,860
8,769
6,588
4,134
Araştırma ve Geliştirme
15,133
13,554
12,450
10,825
9,189
8,662
İşletme Giderleri
29,655
27,192
23,463
19,688
15,996
12,996
Diğer Finansman Gelirleri (Giderleri)
-1
0
2,601
-1
0
-2
Kâr Öncesi Gelir
791
-4,162
-6,208
-13,426
-9,579
-11,248
Kira Vergisi Gideri
944
815
507
215
168
158
Net Kâr
-152
-4,978
-6,715
-13,642
-9,747
-11,383
Net Income Growth
Kâr Artışı
-98%
-26%
-51%
40%
-14%
65%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
1,534.25
1,367.66
1,356.73
1,340.08
1,334.8
1,334.78
Hisse Değişimi (Yıllık Üst Üste)
12%
1%
1%
0%
0%
0%
EPS (Diluted)
-0.09
-3.64
-4.95
-10.18
-7.3
-8.52
EPS Artışı
-98%
-26%
-51%
39%
-14%
65%
Öz sermaye akışı
3,318
-4,677
-11,899
-10,134
-10,541
-6,171
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
85.98%
84.33%
84.44%
80.1%
86.01%
77.07%
Faaliyet Kâr Marjı
2.85%
-15.58%
-50.22%
-125.7%
-124.77%
-535.94%
Kâr Marjı
-0.42%
-18.29%
-38.54%
-142.6%
-128.45%
-536.93%
Özsermaye Karlılık Oranı
9.3%
-17.18%
-68.29%
-105.93%
-138.91%
-291.08%
EBITDA
--
-3,656
-8,387
-11,699
-9,119
-11,015
EBITDA Marjinali
--
-13.43%
-48.13%
-122.29%
-120.17%
-519.57%
D&A EBITDA için
--
585
363
326
349
347
Faaliyet Kârı
1,020
-4,241
-8,750
-12,025
-9,468
-11,362
Faaliyet Kâr Marjı
2.85%
-15.58%
-50.22%
-125.7%
-124.77%
-535.94%
Verilen Vergi Oranı
119.34%
-19.58%
-8.16%
-1.6%
-1.75%
-1.4%
Önemli İstatistikler
Önceki Kapanış
$346.42
Açılış fiyatı
$345.19
Günün Aralığı
$345.07 - $351.87
52 haftalık aralık
$196.45 - $385.22
İşlem hacmi
112.2K
Ort.Hacim
290.8K
EPS (TTM)
0.51
Dividend yield
--
Piyasa Değeri
$35.2B
BeOne Medicines Ltd. nedir?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.